Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 252

The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.

Ligelizumab for Chronic Spontaneous Urticaria

Open access
Maurer, Marcus, Giménez-Arnau, Ana M., Sussman, Gordon, Metz, Martin, Baker, Diane R., Bauer, Andrea, Bernstein, Jonathan A., Brehler, Randolf, Chu, Chia-Yu, Chung, Wen-Hung, Danilycheva, Inna, Grattan, Clive, Hébert, Jacques, Katelaris, Constance, Makris, Michael, Meshkova, Raisa, Savic, Sinisa, Sinclair, Rodney, Sitz, Karl, Staubach, Petra, Wedi, Bettina, Löffler, Jürgen, Barve, Avantika, Kobayashi, Kenneth, Hua, Eva, Severin, Thomas, Janocha, Reinhold·2019·New England Journal of Medicine

Abstract

BACKGROUNDIn the majority of patients with chronic spontaneous urticaria, most currently available therapies do not result in complete symptom control.Ligelizumab is a nextgeneration high-affinity humanized monoclonal anti-IgE antibody.Data are limited regarding the dose-response relationship of ligelizumab and the efficacy and safety of ligelizumab as compared with omalizumab and placebo in patients who have moderate-to-severe chronic spontaneous urticaria that is inadequately controlled with H 1 -antihistamines at approved or increased doses, alone or in combination with H 2 -antihistamines or leukotriene-receptor antagonists. METHODSIn a phase 2b dose-finding trial, we randomly assigned patients to receive ligelizumab at a dose of 24 mg, 72 mg, or 240 mg, omalizumab at a dose of 300 mg, or placebo, administered subcutaneously every 4 weeks for a period of 20 weeks, or a single 120-mg dose of ligelizumab.Disease symptoms of hives, itch, and angioedema were monitored by means of weekly activity scores.The main objective was to determine a dose-response relationship for the complete control of hives (indicated by a weekly hives-severity score of 0, on a scale from 0 to 21, with higher scores indicating greater severity); the primary end point of this response was assessed at week 12. Complete symptom control was indicated by a weekly urticaria activity score of 0 (on a scale from 0 to 42, with higher scores indicating greater severity).Safety was analyzed throughout the trial. RESULTSA total of 382 patients underwent randomization.At week 12, a total of 30%, 51%, and 42% of the patients treated with 24 mg, 72 mg, and 240 mg, respectively, of ligelizumab had complete control of hives, as compared with 26% of the patients in the omalizumab group and no patients in the placebo group.A dose-response relationship was established.At week 12, a total of 30%, 44%, and 40% of the patients treated with 24 mg, 72 mg, and 240 mg, respectively, of ligelizumab had complete control of symptoms, as compared with 26% of the patients in the omalizumab group and no patients in the placebo group.In this small and short trial, no safety concerns regarding ligelizumab or omalizumab emerged. CONCLUSIONSA higher percentage of patients had complete control of symptoms of chronic spontaneous urticaria with ligelizumab therapy of 72 mg or 240 mg than with omalizumab or placebo.(Funded by Novartis Pharma; ClinicalTrials.govnumber, NCT02477332.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1056/nejmoa1900408

Cites

1 of 1 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 1 references

Cited by

See all 252

Metadata

Authors
Maurer, M., Giménez-Arnau, A. M., Sussman, G., Metz, M., Baker, D. R., Bauer, A., Bernstein, J. A., Brehler, R., Chu, C.-Y., Chung, W.-H., Danilycheva, I., Grattan, C., Hébert, J., Katelaris, C., Makris, M., Meshkova, R., Savic, S., Sinclair, R., Sitz, K., Staubach, P., Wedi, B., Löffler, J., Barve, A., Kobayashi, K., Hua, E., Severin, T., & Janocha, R.
Venue
New England Journal of Medicine
Published
2019-10-03
Volume
381
Issue
14
Pages
1321-1332
ISSN
  • 0028-4793 (ISSN-L)
  • 1533-4406
OpenAlex
W2978592627
Cited by
252
References
1
FWCI
26.04
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Ligelizumab for Chronic Spontaneous Urticaria. https://app.cochat.ai/papers/10.1056/nejmoa1900408
The paper
Maurer, M., Giménez-Arnau, A. M., Sussman, G., Metz, M., Baker, D. R., Bauer, A., Bernstein, J. A., Brehler, R., Chu, C.-Y., Chung, W.-H., Danilycheva, I., Grattan, C., Hébert, J., Katelaris, C., Makris, M., Meshkova, R., Savic, S., Sinclair, R., Sitz, K., . . . Janocha, R. (2019). Ligelizumab for Chronic Spontaneous Urticaria. New England Journal of Medicine. https://doi.org/10.1056/nejmoa1900408

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.